Natco Pharma Ltd
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1]
NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.[2]
- Market Cap ₹ 24,596 Cr.
- Current Price ₹ 1,375
- High / Low ₹ 1,639 / 752
- Stock P/E 13.4
- Book Value ₹ 382
- Dividend Yield 0.69 %
- ROCE 29.1 %
- ROE 25.4 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 29.3%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE 400 MidSmallCap Index BSE 250 SmallCap Index Nifty Smallcap 50 Nifty Smallcap 250 Nifty 500 Multicap 50:25:25
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
558 | 622 | 716 | 1,059 | 1,958 | 2,091 | 1,986 | 1,790 | 1,654 | 1,768 | 2,351 | 3,569 | 4,120 | |
401 | 436 | 487 | 778 | 1,266 | 1,163 | 1,170 | 1,212 | 1,236 | 1,555 | 1,506 | 1,929 | 1,875 | |
Operating Profit | 157 | 187 | 229 | 281 | 692 | 928 | 816 | 578 | 418 | 213 | 845 | 1,640 | 2,245 |
OPM % | 28% | 30% | 32% | 26% | 35% | 44% | 41% | 32% | 25% | 12% | 36% | 46% | 54% |
0 | 16 | -2 | 13 | 13 | 39 | 130 | 124 | 101 | 95 | 86 | 102 | 157 | |
Interest | 25 | 34 | 30 | 22 | 18 | 15 | 19 | 21 | 11 | 13 | 9 | 14 | 16 |
Depreciation | 20 | 27 | 42 | 50 | 54 | 66 | 80 | 98 | 115 | 138 | 151 | 172 | 175 |
Profit before tax | 112 | 141 | 154 | 222 | 634 | 888 | 847 | 583 | 392 | 156 | 771 | 1,555 | 2,211 |
Tax % | 30% | 22% | 1% | 20% | 22% | 21% | 21% | 19% | 21% | 11% | 17% | 16% | |
78 | 110 | 153 | 176 | 495 | 698 | 667 | 474 | 310 | 139 | 637 | 1,307 | 1,838 | |
EPS in Rs | 4.98 | 6.66 | 9.20 | 10.13 | 28.39 | 37.84 | 36.48 | 26.06 | 16.97 | 7.62 | 34.90 | 72.95 | 102.65 |
Dividend Payout % | 16% | 15% | 11% | 12% | 24% | 22% | 17% | 26% | 31% | 59% | 16% | 13% |
Compounded Sales Growth | |
---|---|
10 Years: | 19% |
5 Years: | 12% |
3 Years: | 29% |
TTM: | 30% |
Compounded Profit Growth | |
---|---|
10 Years: | 28% |
5 Years: | 15% |
3 Years: | 66% |
TTM: | 74% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | 20% |
3 Years: | 19% |
1 Year: | 72% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 13% |
3 Years: | 15% |
Last Year: | 25% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 31 | 33 | 33 | 35 | 35 | 37 | 36 | 36 | 36 | 36 | 36 | 36 | 36 |
Reserves | 506 | 700 | 846 | 1,302 | 1,665 | 3,088 | 3,527 | 3,833 | 4,055 | 4,155 | 4,666 | 5,556 | 6,807 |
336 | 237 | 309 | 110 | 221 | 173 | 384 | 314 | 256 | 400 | 161 | 366 | 203 | |
184 | 206 | 207 | 396 | 427 | 438 | 408 | 463 | 405 | 387 | 525 | 596 | 765 | |
Total Liabilities | 1,057 | 1,176 | 1,395 | 1,843 | 2,347 | 3,736 | 4,356 | 4,647 | 4,752 | 4,978 | 5,388 | 6,554 | 7,811 |
471 | 529 | 573 | 706 | 829 | 1,015 | 1,215 | 1,574 | 2,006 | 2,174 | 2,234 | 2,287 | 2,360 | |
CWIP | 78 | 93 | 101 | 212 | 336 | 480 | 638 | 518 | 223 | 129 | 63 | 134 | 230 |
Investments | 78 | 89 | 131 | 94 | 95 | 150 | 244 | 191 | 337 | 550 | 658 | 742 | 808 |
431 | 465 | 590 | 831 | 1,087 | 2,091 | 2,259 | 2,363 | 2,186 | 2,125 | 2,434 | 3,392 | 4,413 | |
Total Assets | 1,057 | 1,176 | 1,395 | 1,843 | 2,347 | 3,736 | 4,356 | 4,647 | 4,752 | 4,978 | 5,388 | 6,554 | 7,811 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
70 | 172 | 125 | 190 | 330 | 476 | 699 | 422 | 184 | 58 | 784 | 1,196 | |
-123 | -131 | -148 | -248 | -291 | -1,131 | -645 | -165 | -3 | -92 | -437 | -960 | |
29 | -41 | 23 | 151 | -46 | 652 | -52 | -261 | -183 | 36 | -347 | -237 | |
Net Cash Flow | -24 | 0 | -1 | 93 | -6 | -3 | 1 | -4 | -3 | 1 | 1 | -1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 83 | 68 | 96 | 88 | 87 | 106 | 90 | 109 | 88 | 119 | 123 | 110 |
Inventory Days | 284 | 392 | 424 | 501 | 215 | 400 | 547 | 482 | 562 | 476 | 424 | 379 |
Days Payable | 213 | 240 | 247 | 385 | 160 | 231 | 217 | 215 | 102 | 96 | 126 | 116 |
Cash Conversion Cycle | 153 | 220 | 274 | 205 | 142 | 275 | 420 | 376 | 548 | 499 | 422 | 373 |
Working Capital Days | 75 | 78 | 106 | 119 | 114 | 252 | 285 | 374 | 353 | 348 | 238 | 190 |
ROCE % | 18% | 19% | 18% | 18% | 39% | 34% | 24% | 14% | 9% | 3% | 16% | 29% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
2h - Transcript of Q2 FY25 earnings conference call.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
5h - Natco Pharma submits ANDA for Risdiplam for Oral Solution.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
1d - Sale of investment in ISCA, Inc. for USD 2.06 million.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
-
Announcement under Regulation 30 (LODR)-Change in Management
15 Nov - Mr. Madhava Rao appointed as Associate VP in Pharma Division.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT REC
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jul 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Sep 2019TranscriptNotesPPT
-
Aug 2019TranscriptPPT
-
Jun 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Nov 2017Transcript PPT
-
Aug 2017Transcript PPT
-
May 2017TranscriptPPT
-
Feb 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Sep 2016TranscriptNotesPPT
-
Aug 2016TranscriptPPT
-
Jun 2016TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
Exports of formulations - Complex Generics [1]
The company is focused on niche opportunities in the US.
Focus on Para IV and First-to-File molecules
Started winning tenders in Asian markets including Malaysia and Thailand
Company is focused on high-barrier-to-entry products that are typically characterized by one or more of the following: Intricate Chemistry, Challenging delivery systems, Difficult or complex manufacturing process